Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cethromycin - Advanced Life Sciences/ Abbott Laboratories

Drug Profile

Cethromycin - Advanced Life Sciences/ Abbott Laboratories

Alternative Names: A-195773; A-195773-0; Abbott-195773; ABT 773; Restanza

Latest Information Update: 06 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Advanced Life Sciences; National Institute of Allergy and Infectious Diseases; Taisho Pharmaceutical; United States Army Medical Research Institute of Infectious Diseases; Walter Reed Army Institute of Research
  • Class Antibacterials; Ketolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Plague; Tularaemia; Anthrax
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Anthrax; Community-acquired pneumonia; Gonorrhoea; Malaria; Melioidosis; Plague; Tularaemia
  • Discontinued Acute sinusitis; Bacterial infections; Clostridium-difficile-infections; Toxoplasmosis

Most Recent Events

  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Canada (PO)
  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Europe (PO)
  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top